Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
- Marks successful completion of full enrollment of SAD cohorts and the first two MAD cohorts in the healthy volunteer study - Up to 10 adult participants with genetically confirmed Duchenne...
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) (“Satellos”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and...
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no safety concerns and initiated enrollment of first...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf - No adverse events and no significant...
- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in Q4 2024 - Initiation of the second component of...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.05 | 6.02409638554 | 0.83 | 0.89 | 0.81 | 295370 | 0.8699015 | CS |
| 4 | 0.18 | 25.7142857143 | 0.7 | 1.32 | 0.69 | 254098 | 0.92672157 | CS |
| 12 | 0.39 | 79.5918367347 | 0.49 | 1.32 | 0.485 | 181863 | 0.8326116 | CS |
| 26 | 0.36 | 69.2307692308 | 0.52 | 1.32 | 0.45 | 111290 | 0.74695529 | CS |
| 52 | 0.26 | 41.935483871 | 0.62 | 1.32 | 0.38 | 92454 | 0.6858677 | CS |
| 156 | 0.26 | 41.935483871 | 0.62 | 1.32 | 0.38 | 92454 | 0.6858677 | CS |
| 260 | 0.26 | 41.935483871 | 0.62 | 1.32 | 0.38 | 92454 | 0.6858677 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
